SCHEMBL922480

SCHEMBL922480

CCNC1=NN=CC1=NNc1cccnc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.37
TRPV1 Q8NER1 2/20 0.34
ALDH1A1 P00352 2/20 0.34
PKM P14618 2/20 0.34
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
LTA4H P09960 1/20 0.33
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.32
ABCC9 O60706 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
ABCC8 Q09428 1/20 0.32
KCNJ11 Q14654 1/20 0.32
KCNJ8 Q15842 1/20 0.32
PGK1 P00558 1/20 0.32
KDM4E B2RXH2 2/20 0.32
MAPK1 P28482 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL922478 1.00 RAB9A (0.37) RAB9ATRPV1ALDH1A1PKMLMNA
SCHEMBL922507 0.76 RAB9A (0.40) RAB9ATRPV1ALDH1A1LMNAPOLB
SCHEMBL922506 0.76 RAB9A (0.40) RAB9ATRPV1ALDH1A1LMNAPOLB
SCHEMBL922577 0.76 ALDH1A1 (0.40) TRPV1ALDH1A1LMNAKMT2AMEN1
SCHEMBL922576 0.76 ALDH1A1 (0.40) TRPV1ALDH1A1LMNAKMT2AMEN1
Ammonia Solution, Strong SCHEMBL6618697 0.72 MAPT (0.37) RAB9AALDH1A1PKMLMNAKMT2A
SCHEMBL923056 0.72 CA2 (0.42) RAB9AKMT2AMEN1SMN1; SMN2NPC1
SCHEMBL1355489 0.71
Hydrochloric Acid SCHEMBL10704335 0.69 RAB9A (0.56) RAB9ATRPV1ALDH1A1PKMLMNA
Hydrochloric Acid SCHEMBL28089121 0.69 RAB9A (0.56) RAB9ATRPV1ALDH1A1PKMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 RAB9A 4545/4885TRPV1 2582/4885ALDH1A1 1614/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 RAB9A 4545/4885TRPV1 2582/4885ALDH1A1 1614/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC RAB9A 3555/4885TRPV1 2287/4885ALDH1A1 3393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.